SIGMA HEALTHCARE LIMITED (SIG)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SIG - SIGMA HEALTHCARE LIMITED

FNArena Sector : Health & Nutrition
Year End: January
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -5.88
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.075

21 Feb
2024

-0.015

OPEN

$1.09

-1.38%

HIGH

$1.10

3,088,693

LOW

$1.07

TARGET
$0.898 -16.4% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
CLV . EBO . EXL . MCP .
FNARENA'S MARKET CONSENSUS FORECASTS
SIG: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx 0.2 0.7 xxx
DPS (cps) xxx 1.0 0.9 xxx
EPS Growth xxx N/A 100.0% xxx
DPS Growth xxx - 50.0% - 8.9% xxx
PE Ratio xxx N/A 166.2 xxx
Dividend Yield xxx N/A 0.8% xxx
Div Pay Ratio(%) xxx 538.9% 135.9% xxx

Dividend yield today if purchased 3 years ago: 1.43%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.90

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 30/03 - ex-div 0.5c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx0.2
DPS All xxxxxxxxxxxxxxx1.0
Sales/Revenue xxxxxxxxxxxxxxx3,660.2 M
Book Value Per Share xxxxxxxxxxxxxxx46.5
Net Operating Cash Flow xxxxxxxxxxxxxxx142.7 M
Net Profit Margin xxxxxxxxxxxxxxx0.05 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx0.38 %
Return on Invested Capital xxxxxxxxxxxxxxx0.25 %
Return on Assets xxxxxxxxxxxxxxx0.15 %
Return on Equity xxxxxxxxxxxxxxx0.38 %
Return on Total Capital xxxxxxxxxxxxxxx-9.09 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx98.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx13 M
Long Term Debt xxxxxxxxxxxxxxx214 M
Total Debt xxxxxxxxxxxxxxx227 M
Goodwill - Gross xxxxxxxxxxxxxxx95 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx17 M
Price To Book Value xxxxxxxxxxxxxxx1.32

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx29.4 M
Capex % of Sales xxxxxxxxxxxxxxx0.80 %
Cost of Goods Sold xxxxxxxxxxxxxxx3,436 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx293 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx16 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

5

xxxxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Shaw and Partners

15/12/2023

3

Downgrade to Hold from Buy

$0.90

-16.28%

Sigma Healthcare's share price is up circa 37% since it announced its intended merger with Chemist Warehouse. Based on the information released, Shaw and Partners estimates that this is effectively a nil premium/discount merger.

As the transaction is subject to regulatory approval, the broker makes no changes to forecasts at this time. Given the current share price, and the regulatory review process that will likely take several months, the broker downgrades to Hold from Buy.

90c target retained.

FORECAST
Shaw and Partners forecasts a full year FY24 dividend of 1.00 cents and EPS of 0.90 cents.
Shaw and Partners forecasts a full year FY25 dividend of 1.00 cents and EPS of 1.40 cents.

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

SIG STOCK CHART